Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

This is an Open Label Study to Evaluate the Efficacy of Intravitreal Aflibercept Injection 2mg in Patients With a Persistent FVPED Despite at Least 6 Consecutive Injections With Ranibizumab 0.5 mg

NCT01495208 is registered in ClinicalTrials.gov with Vitreous -Retina- Macula Consultants of New York as lead sponsor.

NCT NCT01495208
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01495208 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
This is an Open Label Study to Evaluate the Efficacy of Intravitreal Aflibercept Injection 2mg in Patients With a Persistent FVPED Despite at Least 6 Consecutive Injections With Ranibizumab 0.5 mg
Lead sponsor
Vitreous -Retina- Macula Consultants of New York
Phase
Phase 4
Overall status
Withdrawn
Start date
December 31, 2011
Completion date
October 31, 2012
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

fibrovascular pigment epithelial detachment